01.13.21 #NoGoingBack Supports Keeping Patients First
The
Business Of Biotech Cell & Gene Miniseries opens with Dr. Carsten Brunn, president and CEO of Selecta Biosciences. Guest host Erin Harris joins our discussion on Selecta s ImmTOR platform and how the company is addressing the immunogenicity of adeno-associated virus (AAV) vectors challenge faced by gene therapy companies. Listen now and subscribe so you never miss an episode.
Featured Editorial
By Ed Miseta, chief editor, Clinical Leader
#NoGoingBack has been gaining a lot of attention of late. Founded by Signant Health and supported (and chaired) by industry leaders such as Craig Lipset of Clinical Innovation Partners and Allyson Small of SCRS, the group has been pushing for permanent adoption of the trial changes implemented in 2020 to keep patients safe from COVID-19 and drive often-discussed innovation into standard trial practice.